Erratum: The challenges and concerns companies face pertaining to the US Food and Drug Administration 510(k) process for cardiac biomarkers (Clinical Chemistry (2012) 58 (31-38) DOI: 10.1373/clinchem.2011.165860);The challenges and concerns companies face pertaining to the US Food and Drug Administration 510(k) process for cardiac biomarkers

Clinical Chemistry

Volumn 58, Issue 1, 2012, Pages 31-38

  Apple, Fred S ^a,b   Morrow, David ^c   Zaugg, Christian ^d   Hickey, David ^e   Zaharik, Michelle ^f   Blackwood, John J ^g   Jakobsen, Kirsten ^h  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Medical and Scientific Affairs   (Switzerland)

^e Siemens Healthcare Diagnostics Inc   (United States)

^f Response Biomedical   (Canada)

^g Product Management   (United States)

^h Radiometer Medical   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

TROPONIN I; TROPONIN T;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; CLINICAL STUDY; COMORBIDITY; DIAGNOSTIC TEST ACCURACY STUDY; EMERGENCY WARD; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEART INJURY; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HUMAN; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NOTE; PREVALENCE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; ST SEGMENT ELEVATION; STATISTICAL ANALYSIS; UNITED STATES;

EID: 84856076527     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.182949     Document Type: Erratum

References (0)